Skip to main content
. 2019 Sep 9;9:12901. doi: 10.1038/s41598-019-49579-y

Figure 1.

Figure 1

Platform technology for ectopic antigen expression using BC-PIV. (a) Graphic depiction of the production of recombinant vaccines. Antigen genes are inserted into the cloning site (CS) 1 and/or CS2 of BC-PIV, and the resultant vectors are produced by the reverse genetics method13,5. (b) Another method for antigen expression as a fusion protein with the C-terminus of HN of BC-PIV, and/or that of F from packaging cells. (c) A Western blot analysis of EBOV-GP on BC-PIV using 1 × 106 particles/lane. The authentic or hybrid EBOV GP gene was inserted into CS2 of BC-PIV. F TM&CT, transmembrane and cytoplasmic tail regions of hPIV2 F. (d) A Western blot analysis of M2e peptide fused with hPIV2 HN and/or F on BC-PIV using 1 × 106 particles/lane.